ERC treatment significantly reduced the levels of TNF-Alpha, IL-1Beta and IL-6; ERCs downregulated the expanded Th1 and Th17 cells in colitis, and elevated the proportion of Tregs in lymphocytes; ERCs inhibited B-cell activation, differentiation and IgG production in colitis. ERC treatment enhanced the concentration of IL-10 in the colon and spleen, as well as CD1dhiCD5 + B cells in the spleen, peritoneal cavity and MLN. This evidence concerns the gene TNF and colitis.